Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
97 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Genital Herpes - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H2 2017, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape. Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Genital Herpes - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 3, 17 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Genital Herpes - Overview 6 Genital Herpes - Therapeutics Development 7 Pipeline Overview 7 Pipeline by Companies 8 Pipeline by Universities/Institutes 11 Products under Development by Companies 12 Products under Development by Universities/Institutes 14 Genital Herpes - Therapeutics Assessment 15 Assessment by Target 15 Assessment by Mechanism of Action 17 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Genital Herpes - Companies Involved in Therapeutics Development 23 Abivax SA 23 Admedus Ltd 23 AiCuris GmbH & Co KG 24 Biomere LLC 24 Foamix Pharmaceuticals Ltd 25 Genocea Biosciences Inc 25 GenVec Inc 26 Immune Design Corp 26 JN-International Medical Corp 27 NanoBio Corp 27 NanoViricides Inc 28 Profectus BioSciences Inc 28 Redbiotec AG 29 Sanofi Pasteur SA 29 Starpharma Holdings Ltd 30 Vaccibody AS 30 Vical Inc 31 Genital Herpes - Drug Profiles 32 ABX-196 - Drug Profile 32 acyclovir - Drug Profile 33 Aspidasept - Drug Profile 34 astodrimer - Drug Profile 35 G-103 - Drug Profile 40 GEN-003 - Drug Profile 41 genital herpes (virus like particle) vaccine - Drug Profile 47 genital herpes vaccine - Drug Profile 48 genital herpes vaccine - Drug Profile 51 genital herpes vaccine - Drug Profile 52 genital herpes vaccine - Drug Profile 53 genital herpes vaccine - Drug Profile 54 GV-2207 - Drug Profile 55 herpes simplex virus [type 1, 2] vaccine - Drug Profile 56 herpes simplex virus 2 vaccine - Drug Profile 57 herpes simplex virus 2 vaccine - Drug Profile 58 herpes simplex virus 2 vaccine - Drug Profile 59 herpes simplex virus 2 vaccine - Drug Profile 61 herpes simplex virus 2 vaccine - Drug Profile 62 HSV-529 - Drug Profile 63 NN-001 - Drug Profile 65 pritelivir - Drug Profile 66 Profavax HSV-1 - Drug Profile 69 Profavax HSV-2 - Drug Profile 70 Small Molecule for Genital Herpes - Drug Profile 71 Theravax HSV-1 - Drug Profile 72 Theravax HSV-2 - Drug Profile 73 VCLHB-01 - Drug Profile 74 VCLHM-01 - Drug Profile 76 VMTX-004 - Drug Profile 78 Genital Herpes - Dormant Projects 79 Genital Herpes - Discontinued Products 81 Genital Herpes - Product Development Milestones 82 Featured News & Press Releases 82 Appendix 94 Methodology 94 Coverage 94 Secondary Research 94 Primary Research 94 Expert Panel Validation 94 Contact Us 94 Disclaimer 95
List of Tables
Number of Products under Development for Genital Herpes, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Genital Herpes - Pipeline by Abivax SA, H2 2017 Genital Herpes - Pipeline by Admedus Ltd, H2 2017 Genital Herpes - Pipeline by AiCuris GmbH & Co KG, H2 2017 Genital Herpes - Pipeline by Biomere LLC, H2 2017 Genital Herpes - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017 Genital Herpes - Pipeline by Genocea Biosciences Inc, H2 2017 Genital Herpes - Pipeline by GenVec Inc, H2 2017 Genital Herpes - Pipeline by Immune Design Corp, H2 2017 Genital Herpes - Pipeline by JN-International Medical Corp, H2 2017 Genital Herpes - Pipeline by NanoBio Corp, H2 2017 Genital Herpes - Pipeline by NanoViricides Inc, H2 2017 Genital Herpes - Pipeline by Profectus BioSciences Inc, H2 2017 Genital Herpes - Pipeline by Redbiotec AG, H2 2017 Genital Herpes - Pipeline by Sanofi Pasteur SA, H2 2017 Genital Herpes - Pipeline by Starpharma Holdings Ltd, H2 2017 Genital Herpes - Pipeline by Vaccibody AS, H2 2017 Genital Herpes - Pipeline by Vical Inc, H2 2017 Genital Herpes - Dormant Projects, H2 2017 Genital Herpes - Dormant Projects, H2 2017 (Contd..1), H2 2017 Genital Herpes - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.